ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Ascelia Pharma company presentation May 2020

Download our fact sheet: Ascelia Pharma factsheet

Lead candidate Mangoral (Phase III) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• August 20 @ 08:00

  Half-year financial report 2020 (Jan-Jun)

• September 2 @ 08:00 - 17:00

  Pareto Securities’ Healthcare conference

• November 5 @ 08:00

  Interim financial report 9M 2020 (Jan-Sep)

• 2021-02-16 @ 08:00

  Full-year financial report 2020 (Jan-Dec)

• 2020-05-20Updated SPARKLE timelines due to Covid-19 impact
• 2020-05-13Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE
• 2020-05-06Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2020
• 2020-05-06First participant enrolled in the clinical hepatic impairment study with Mangoral
• 2020-04-16Patent for Oncoral approved in Japan